Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001140361-25-022544
Filing Date
2025-06-16
Accepted
2025-06-16 08:00:19
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 17028
2 EXHIBIT 1 ef20050649_ex1.htm EX-1 690442
3 image0.jpg GRAPHIC 21639
  Complete submission text file 0001140361-25-022544.txt   739206
Mailing Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102
Business Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102 (650) 938-6300
23andMe Holding Co. (Subject) CIK: 0001804591 (see all company filings)

EIN.: 871240344 | Fiscal Year End: 0331
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91734 | Film No.: 251048563
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 171 MAIN STREET SUITE 259 LOS ALTOS CA 94022
Business Address 171 MAIN STREET SUITE 259 LOS ALTOS CA 94022 650-209-9500
ABeeC 2.0, LLC (Filed by) CIK: 0001869643 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13D/A